CRIS Current Research Information System

RINALDI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.857
EU - Europa 2.334
NA - Nord America 2.134
SA - Sud America 236
AF - Africa 172
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.753
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.088
CN - Cina 1.431
SG - Singapore 1.272
IT - Italia 1.179
VN - Vietnam 340
KR - Corea 284
DE - Germania 227
HK - Hong Kong 220
BR - Brasile 174
SE - Svezia 170
NL - Olanda 153
IN - India 149
GB - Regno Unito 136
CI - Costa d'Avorio 85
FI - Finlandia 74
IE - Irlanda 70
RU - Federazione Russa 70
JP - Giappone 64
FR - Francia 61
AT - Austria 46
CH - Svizzera 33
AR - Argentina 32
ID - Indonesia 28
CA - Canada 26
BG - Bulgaria 23
ES - Italia 22
TG - Togo 21
JO - Giordania 19
SC - Seychelles 18
AU - Australia 17
NG - Nigeria 17
PL - Polonia 15
UA - Ucraina 15
ZA - Sudafrica 15
MX - Messico 14
BE - Belgio 13
BD - Bangladesh 9
EC - Ecuador 9
IQ - Iraq 8
IR - Iran 6
LT - Lituania 6
TR - Turchia 6
CL - Cile 5
HR - Croazia 5
MA - Marocco 5
PE - Perù 5
PY - Paraguay 5
GR - Grecia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CY - Cipro 3
HN - Honduras 3
KE - Kenya 3
AL - Albania 2
AZ - Azerbaigian 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
MY - Malesia 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
AO - Angola 1
BZ - Belize 1
CO - Colombia 1
EU - Europa 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MU - Mauritius 1
NA - Namibia 1
NZ - Nuova Zelanda 1
PG - Papua Nuova Guinea 1
PH - Filippine 1
RE - Reunion 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UY - Uruguay 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 8.753
Salva come PNG Salva come JPEG
Città #
Singapore 862
Hefei 711
Ashburn 425
Seoul 284
Bologna 261
Hong Kong 218
Chandler 188
Santa Clara 167
Milan 136
Ho Chi Minh City 119
Dallas 111
Beijing 102
Hanoi 88
Abidjan 85
Dublin 68
Bengaluru 67
Boardman 66
Southend 64
Los Angeles 60
Rome 58
Tokyo 58
Fairfield 57
New York 57
Princeton 44
Munich 42
Castel Maggiore 35
Helsinki 34
Shanghai 32
Nuremberg 30
Redondo Beach 30
Buffalo 29
Turin 29
Vienna 28
Wilmington 28
Lappeenranta 26
Florence 25
Verona 24
Jakarta 22
Seattle 22
Sofia 22
Woodbridge 22
Berlin 21
Bern 21
Houston 21
Lomé 21
Amman 19
Tongling 19
Falkenstein 18
Genoa 18
Reggio Emilia 18
São Paulo 17
Abeokuta 16
Amsterdam 16
Frankfurt am Main 16
Denver 15
Guangzhou 15
Boydton 14
Modena 14
Chicago 13
Turku 13
Bremen 12
Brussels 12
Des Moines 12
London 12
Toronto 12
Ann Arbor 11
Budrio 11
Johannesburg 11
San Diego 11
Tappahannock 11
Washington 11
Adelaide 10
Cambridge 10
Council Bluffs 10
Haiphong 10
Redmond 10
Ha Long 9
Nanjing 9
Bắc Ninh 8
Cesena 8
Da Nang 8
Naples 8
Boston 7
Changsha 7
Chennai 7
Hyderabad 7
Padova 7
Paris 7
Parma 7
Quận Bình Thạnh 7
Shenzhen 7
Yubileyny 7
Belo Horizonte 6
Buenos Aires 6
Casalecchio di Reno 6
Cincinnati 6
Ferrara 6
Jinan 6
Mexico City 6
Rio de Janeiro 6
Totale 5.505
Salva come PNG Salva come JPEG
Nome #
Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort 229
Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort 210
Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study 209
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 207
Artificial Intelligence model to predict resistances in Gram-negative bloodstream infections 199
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 199
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study 190
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study 178
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 161
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study 160
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 158
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 153
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 152
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study 150
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 149
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 145
Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study 143
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 140
A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study 140
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 140
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 139
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 139
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 138
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 138
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 136
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 132
Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacterales infection 131
Risk factors for candidemia in hospitalized patients with liver cirrhosis: a multicenter case-control-control study 127
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 124
Antimicrobial Resistance in Organ Transplant Recipients 123
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 121
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study 121
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 120
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 120
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 119
Development of a Risk Prediction Model for Carbapenem-resistant Enterobacteriaceae Infection after Liver Transplantation: A Multinational Cohort Study 117
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 116
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 115
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections 114
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 114
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study 111
Is CMV DNAemia an early marker of CMV colitis in patients with active ulcerative colitis? 111
The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study 111
Predictive model for bacterial co-infection in patients hospitalized for COVID-19: a multicenter observational cohort study 111
Prediction models for carbapenem-resistant Enterobacterales carriage at liver transplantation: A multicenter retrospective study 109
Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort 107
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients 101
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 100
LA CONTAMINAZIONE DEL LIQUIDO DI PERFUSIONE DELL’ORGANO NEL TRAPIANTO DI FEGATO:INCIDENZA, PROFILO MICROBIOLOGICO ED IMPATTO CLINICO. 98
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment 96
Epidemiological characteristics and management of Gram-negative bacteraemia in different immunocompromised hosts: Observational single-center study 95
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 93
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia? 92
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient 89
Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literature 87
Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study 87
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia 87
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae 85
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 85
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections 83
Is acidemia at birth a risk factor for functional gastrointestinal disorders? 82
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies 76
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis 75
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 74
Survey on the approach to antibiotic prophylaxis in liver and kidney transplant recipients colonized with “difficult to treat” Gram‐negative bacteria 71
Use of colistin in adult patients: A cross-sectional study 67
Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" 66
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 61
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 59
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study 56
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible Enterococcus faecium 56
Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project 54
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study 53
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients 52
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis 42
Invasive aspergillosis in liver transplant recipientsin the current era 38
TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients 33
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in haematological patients 33
Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion 29
Exploring heterogeneity in antibiotic choices for bloodstream infections caused by AmpC-producing enterobacterales: results from a case-vignette study 24
HHV8-related diseases in solid organ transplantation: a case series and systematic literature review 24
Use of isavuconazole in critically ill patients in intensive care units: A prospective, observational, multicentre, cohort study 22
Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study 17
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? 13
Diagnosis and management of invasive candidiasis in critically ill patients: SIAARTI multidisciplinary statement 5
Validation of a predictive risk score of aggressive PK/PD target non-attainment with continuous infusion piperacillin/tazobactam or meropenem in critically ill patients having documented Gram-negative infections 3
Totale 9.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021167 0 0 0 0 0 8 15 10 46 34 19 35
2021/2022523 19 18 15 49 32 25 18 57 29 80 105 76
2022/2023883 52 96 30 93 106 81 35 65 163 35 63 64
2023/2024742 71 61 53 70 71 97 42 37 42 69 69 60
2024/20252.597 76 211 207 175 270 124 258 126 85 214 336 515
2025/20263.982 747 976 754 758 620 127 0 0 0 0 0 0
Totale 9.039